Print this page

Adults With Pemphigus Vulgaris (PV)

Adults With Pemphigus Vulgaris (PV)

PARTICIPANTS NEEDED

A Randomized, Double-Blind, Double-Dummy, Active-Comparator, Multicenter Study To Evaluate The Efficacy And Safety Of Rituximab Versus MMF In Patients With Pemphigus Vulgaris

SLU IRB #25123

Pemphigus Vulgaris (PV) is a rare, severe autoimmune disease that causes fragile blisters on the skin and in the mouth.  The blisters may become painful or infected.  Standard treatment generally includes treatment with corticosteroid medications.

This research is evaluating two different investigational medications to see if they can help people who have Pemphigus Vulgaris (PV). The purpose of this study is to assess the safety, tolerability, and effectiveness of the medications in people with PV. Participants will receive one of the two investigational (active) medications and one placebo (non-active) medication.

Your participation may last up to 52 weeks during treatment and another 48 weeks of follow up after the last treatment dose.

You must meet the following criteria to become a study participant:

  • Are 18-75 years of age
  • Have a confirmed diagnosis of PV within the previous 24 months
  • Are willing to follow a study treatment plan, routinely scheduled study visits and other

Study tests and procedures:

  • Are in stable health
  • Meet other entry criteria based on screening examinations

You will receive the following:

  • One investigational medication and one placebo medication
  • Study required physical exams and laboratory tests
  • Compensation for time and travel

 

For more information contact:

Anastasia Kurta, DO

Dermatology Research Fellow
(314) 256-3439
kurtaao@slu.edu